Abstract

Infection with Schistosoma haematobium leads to urogenital schistosomiasis, which has been correlated with the occurrence of bladder cancer. However, mechanisms responsible for this association have not yet been clearly identified. In this short review, we provide an update, highlighting the most recent studies on schistosome-associated bladder cancer, including those that focus on identifying changes in host biology during S. haematobium infection, as well as studies for the identification of potentially pro-carcinogenic parasite molecules, and we offer a discussion on some possible mechanisms driving schistosomal bladder cancer.

Highlights

  • Specialty section: This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

  • We provide an update, highlighting the most recent studies on schistosome-associated bladder cancer, including those that focus on identifying changes in host biology during S. haematobium infection, as well as studies for the identification of potentially pro-carcinogenic parasite molecules, and we offer a discussion on some possible mechanisms driving schistosomal bladder cancer

  • Regarding the cost of treatment, a recent cost analysis estimated about 18 million USD for praziquantel administration (0.16 USD per person for approximately 112 million people infected with S. haematobium), compared to an annual incrementing cost of 20 million USD for the treatment of schistosomal bladder cancer [12]

Read more

Summary

SCHISTOSOMA HAEMATOBIUM AND BLADDER CANCER

As with other members of the Schistosoma genus, infection with S. haematobium leads to schistosomiasis, a debilitating disease affecting more than 200 million people [1]. Regarding the cost of treatment, a recent cost analysis estimated about 18 million USD for praziquantel administration (0.16 USD per person for approximately 112 million people infected with S. haematobium), compared to an annual incrementing cost of 20 million USD for the treatment of schistosomal bladder cancer (an estimated 3-4 patients out of 100,000 people infected with S. haematobium develop bladder cancer each year) [12]. Some recent studies have used bladder tumor biopsy samples, with and without

IDENTIFICATION OF KEY PARASITE MOLECULES
POSSIBLE MECHANISMS OF SCHISTOSOMAL BLADDER CANCER
FUTURE DIRECTIONS IN SCHISTOSOMAL BLADDER CANCER RESEARCH
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call